Ivabradine for POTS: What the Evidence Actually Says

About
Latest Posts

Adam Foster is the founder of The Fibro Guy and one of the leading voices in hypermobility, EDS, and chronic pain rehabilitation. A former Reconnaissance Soldier, he developed chronic pain after an IED blast in Afghanistan and built his approach from the ground up when the medical system had no answers. Since 2009 he has worked with thousands of people across eight countries, drawing on pain neuroscience, motor learning, and sensorimotor rehabilitation. He co-authored "No Pain, No Pain" with trauma psychologist Dr Mairi Harper, directed the documentary "Invisible Monster," and has been featured in Forbes, BBC Radio 4, ITV News, LiveScience, and The Telegraph.

First, why the heart races in the first place

POTS, postural tachycardia syndrome, is defined by one measurable thing: a sustained rise in heart rate of at least 30 beats per minute (40 if you’re between 12 and 19) within ten minutes of standing up, without your blood pressure crashing, and with the symptoms hanging around for at least three months rather than a bad week ^[10]^[12]. That number is the diagnosis. It is not the problem. The tachycardia is the body’s answer to something that sits further upstream.

Here’s what’s going on. When you stand, gravity pulls a chunk of your blood volume down into your legs and abdomen. In most people the vessels clamp down and the volume gets pushed back up to the heart and brain without you noticing a thing. In POTS that return is blunted, usually through some mix of low blood volume, blood pooling low down, and an autonomic nervous system that isn’t regulating the vessels properly ^[16]. The heart is left with less to pump, so to keep enough blood reaching your brain it does the only thing it can: it beats faster, and it leans hard on adrenaline to do it. That’s the racing heart. It’s a compensation, not a fault in the heart itself.

This matters for the whole ivabradine question, because it tells you what any heart rate drug can and can’t do. Slow the heart and you take the edge off the most alarming symptom. You do not refill the blood volume, retrain the vessels, or fix the autonomic signalling. And POTS rarely travels alone. It clusters with joint hypermobility and with mast cell and connective tissue problems, which is a big part of why no single tablet ever sorts the whole thing out. Hold that thought, because it’s the point we come back to at the end.

What ivabradine actually is

Ivabradine is a heart rate drug, but a fussy, specific one. It works by blocking what cardiac physiologists call the funny current, written If, a flow of ions in the pacemaker cells of the sinoatrial node, the little cluster of tissue that sets your heart’s rhythm ^[6]. Those cells slowly leak themselves up to the point where they fire the next beat, and the funny current is a big part of that slow drift. Block it and the drift takes longer, so the node fires less often, and your heart rate comes down. It got the name “funny” decades ago because it behaved unlike the other currents anyone had described, and the odd name just stuck.

Now, here’s the bit that makes it interesting for POTS. It only touches the sinoatrial node. It doesn’t block adrenaline, it doesn’t relax your blood vessels, it doesn’t weaken the squeeze of the heart muscle, and it leaves your blood pressure roughly where it was ^[4]^[6]. If anything, the one nudge it does give blood pressure tends to be gently upward rather than down, which in POTS is the direction you actually want. A beta blocker does the opposite of all this. It reaches across the whole adrenaline system, which is exactly why it can flatten you. Ivabradine is a scalpel where a beta blocker is a blanket.

Worth being honest about its status, though. In the UK and Europe ivabradine (you’ll see it as Procoralan) is licensed for stable angina and for chronic heart failure, not for POTS. In the US it’s sold as Corlanor for heart failure. No regulator has approved it for POTS anywhere, so every time it’s used for this it’s being used off label. That’s not a scandal, off label prescribing is legal and common, but it does mean the evidence base is thinner than it would be for an approved use, and it can affect whether a given doctor is willing to prescribe it and whether it’s easy to get funded.

Why not just a beta blocker?

Beta blockers are still the default, and there’s a decent reason for that beyond habit. Low dose propranolol genuinely does the job for a lot of people: at 20 milligrams it cut the standing tachycardia and eased symptoms in POTS ^[15]. The interesting wrinkle from that same work is that more was not better. A higher 80 milligram dose lowered the heart rate further but did nothing extra for symptoms, and for some people it made them feel worse ^[15]. Less is more, which is not how most people assume drugs are meant to work.

The trouble is the collateral damage. Because a beta blocker works across the whole adrenaline system, it can drag your blood pressure down (already a problem for plenty of people in POTS), leave you tired and heavy limbed, worsen the brain fog, and, because adrenaline signalling reaches the gut too, slow gut motility in people whose digestion is sluggish already. For some, the fatigue trade is worse than the racing heart it was meant to fix. That’s the exact gap ivabradine is supposed to fill: bring the heart rate down without touching blood pressure or blunting the adrenaline system, and hopefully skip the flattening.

It’s a lovely theory. The question, as always, is whether it holds up in actual people, and that’s where you have to look at the studies honestly rather than take the mechanism on trust.

What the evidence actually says

So what does the evidence actually say? Well, let’s start with the strongest pieces, because when it comes to ivabradine in POTS there are now two randomised trials, and it’s worth being clear eyed about both.

The first was a randomised, double blind, placebo controlled trial published in 2021 ^[1]. It enrolled 22 people, all with the hyperadrenergic type of POTS specifically (the subtype driven by high adrenaline output), and each person spent a month on ivabradine and a month on placebo without knowing which was which. Ivabradine significantly lowered the heart rate compared with placebo (p<0.001), and, more meaningfully, quality of life improved on both the physical functioning (p=0.008) and social functioning (p=0.021) scales ^[1]. There was also a strong trend toward lower standing noradrenaline (p=0.056), and no significant slowing of the heart into bradycardia and no blood pressure drop ^[1]. A genuinely good result. It is also 22 people, over one month, in one subtype. Hold both of those facts at once.

The second is newer, and it’s the one that changes the picture a little. In 2026 a randomised crossover trial put ivabradine head to head with propranolol and placebo in people with POTS ^[2]. Both drugs pulled the standing heart rate back below the diagnostic threshold compared with placebo, and here’s the part worth sitting with: there was no significant difference between ivabradine and propranolol on heart rate control (p=0.09) ^[2]. In other words, when you actually test them against each other, ivabradine held its own against the default drug rather than trailing behind it. The same trial found ivabradine nudged systolic blood pressure up slightly more than propranolol did (p=0.001), which, again, in POTS is a point in its favour rather than against ^[2]. It’s still a small trial, but it’s a proper controlled comparison, and it moves ivabradine from “promising alternative” to “stands up next to the thing we usually reach for”.

Everything else is observational, which means case series and cohorts rather than controlled trials. The largest looked at 49 people and found the standing heart rate falling from around 107 to 95 beats per minute, with roughly 38 of them reporting they felt better, and palpitations improving in close to 88 per cent ^[3]. A smaller retrospective series of 20 was more sober: about 60 per cent improved, and a fair number stopped the drug because it wasn’t doing enough for them ^[4]. And a little mechanistic study of just eight people showed a single 7.5 milligram dose dragging the tilted heart rate down from 118 to 101 beats per minute (p<0.01), while, tellingly, not shifting the underlying balance of the autonomic nervous system at all ^[5]. That last detail is the mechanism confirming itself: ivabradine slows the pace, it doesn’t rebalance the system.

Pull it all together and the picture is fairly consistent. Across the pooled data, somewhere around three quarters of people report their symptoms improving ^[8]. On the raw pooled numbers ivabradine’s average heart rate reduction has tended to look more modest than a beta blocker’s ^[8], which for a long time was read as ivabradine being the lighter hitter. The 2026 head to head muddies that story in a good way, because when the two were tested directly, the gap on heart rate control didn’t reach significance ^[2]. Where ivabradine has always looked better is tolerability: people tend to stay on it and report feeling less wrecked. The most thorough systematic review to date, a 2025 review that registered its protocol in advance and searched five databases across 32 studies, sits ivabradine firmly in the “reasonable option with a consistent signal” camp rather than overselling it ^[8]. A separate 2025 systematic review of seven studies and roughly 200 people reached a similar “effective and safe” conclusion, while being upfront that the underlying evidence was still limited ^[7].

That caution is the honest read, and the most recent treatment review makes it plainer still. Looking across the whole POTS treatment field in 2026, the conclusion was blunt: the evidence is thin, and what the area badly needs is large randomised trials of single treatments rather than more small series ^[9]. So that’s where it actually stands, warts and all. The mechanism is sound. The signal across every study points the same way, which is reassuring, and the 2026 head to head is a real step up from where we were. But it still rests on two small trials and a stack of uncontrolled observations, and “most people in a case series felt better” is a much weaker claim than “this beat placebo in a large trial”. Anyone selling ivabradine as a proven POTS cure is running ahead of the data. Anyone dismissing it out of hand has to explain why the results keep pointing in the same direction.

Side effects and the practical realities

When it comes to side effects, the signature one is genuinely strange, and worth knowing about so it doesn’t frighten you if it happens. A fair number of people get brief flashes of brightness in their vision, little halos or shimmering patches, usually when the light changes suddenly. In the largest series it turned up in nine of the 49, and notably none of them stopped the drug because of it ^[3]. The reason is rather neat: the retina carries ion channels closely related to the funny current in the heart, so a drug aimed at the heart’s pacemaker clips the eye’s version too. It’s called phosphenes, or luminous phenomena, it tends to settle over the first few weeks, and it’s generally harmless.

Beyond that, the doses used in the studies have sat roughly in the range of 5 to 15 milligrams a day, usually split into a morning and evening dose and started low ^[3]^[4]^[5], but that is genuinely a decision for your prescriber and not something to eyeball from a blog. A few practical realities are worth flagging. Ivabradine needs your heart to be in a normal sinus rhythm to work, so it isn’t suitable for everyone. It has meaningful interactions with a list of other drugs. And because it’s being used off label for POTS, you may find it needs a cardiologist or an autonomic specialist to initiate rather than a GP, and funding can be a fight. If you’re pregnant or planning to be, it’s one to specifically raise, because the medication picture changes a lot in pregnancy. None of that is a reason to rule it out. It’s a reason to go in with your eyes open.

Where ivabradine fits: the bit most people skip

This is the part that gets left out of almost every article on the drug, and it’s the part that matters most. A medication that slows your heart is managing a symptom. It is not treating the reason your heart is racing. Come back to the mechanism from the start of this post: the tachycardia is a compensation for poor blood return and blunted autonomic control. Ivabradine turns down the compensation. The thing being compensated for is still sitting there.

That’s not an argument against the drug. It’s an argument about where it sits in the queue. When it comes to POTS, the treatments with the best evidence for actually changing the course of the condition are not drugs at all. When exercise training was put head to head with propranolol, both slowed the standing heart rate, but only the exercise arm improved people’s quality of life ^[13]. That’s why structured exercise, built up carefully, is treated as first line therapy rather than a nice extra ^[14], and it’s the same message that runs through the most recent guideline updates. Alongside it sit the unglamorous foundations: rebuilding blood volume with salt and fluid, using compression garments to fight the pooling, and the day to day habits that reduce how often your body has to fire off an adrenaline surge in the first place ^[11]^[12].

There’s a reason so many people bounce off exercise in POTS. If you stand up and your heart rate is already too high before you’ve done anything, upright exercise feels impossible and often backfires. The way through is to start in positions where gravity isn’t fighting you, recumbent bike, rowing, floor work, and build the base before going upright. We’ve written the whole approach up in why the order you exercise in matters more than the effort, and it’s the single most useful thing most people with POTS can do.

This is exactly where ivabradine earns its place, and it’s a real one. If your resting and standing heart rate is so high that you genuinely can’t start any of the foundational work, a drug that brings it into a workable range can buy you the headroom to begin. Used like that, as a tool that lets you get moving and get the basics in, it makes complete sense. Used as a replacement for the basics, so you can keep the heart rate down and skip the rest, it quietly wastes the best chance you’ve got of actually feeling better. The same logic runs through how we think about medication for pain more broadly, and about drugs like amitriptyline or low dose naltrexone: helpful as scaffolding, a problem when they become the whole building.

There’s a knock on effect worth naming too. A heart that’s constantly racing keeps the whole nervous system in a state of alarm, which feeds the anxiety that rides shotgun with POTS and wrecks sleep. Take the edge off the tachycardia and, for some people, that alarm loop settles enough that pacing and exercise stop feeling like climbing a wall. That knock on calming is arguably as valuable as the heart rate number itself, and it doesn’t show up on a tilt table.

So, is it worth asking about?

For the right person, yes, and it’s a reasonable conversation to have. If you’ve tried a beta blocker and the fatigue or the blood pressure drop made it unworkable, ivabradine is the obvious next thing to raise, because it targets the heart rate without the adrenaline wide collateral. The evidence, while still thin, is consistent, now includes a head to head trial where it matched the default drug, and the drug is generally well tolerated. It’s not a first move ahead of the foundations, and it’s not a cure, but as a way to make the racing heart liveable while you do the work that genuinely shifts POTS, it has a real and defensible role. Go into that appointment knowing it’s two small trials and a lot of promising case data, knowing it won’t drop your blood pressure, and knowing what it can’t do, and you’ll have a far better conversation than most.

Frequently Asked Questions

Does ivabradine cure POTS?

No. Ivabradine slows a racing heart by acting on the heart’s pacemaker, but it doesn’t fix the low blood volume, blood pooling, or autonomic signalling that make the heart race in the first place. It manages a symptom. The treatments with the best evidence for changing POTS itself don’t involve medication at all, especially graded exercise built up from recumbent positions, alongside fluids, salt and compression.

Is ivabradine better than a beta blocker for POTS?

Not straightforwardly, but the gap is narrower than people used to think. A 2026 randomised trial put the two head to head and found no significant difference in heart rate control, and ivabradine does its job without dropping blood pressure or blunting the whole adrenaline system, so it often causes less fatigue and is better tolerated. For someone who couldn’t cope with a beta blocker’s side effects, ivabradine is the logical alternative to ask about. Which suits you is a decision for your doctor.

How strong is the evidence for ivabradine in POTS?

Modest but consistent, and improving. There are now two small randomised trials, including a 2021 placebo controlled trial in hyperadrenergic POTS and a 2026 crossover trial against propranolol and placebo. The rest is case series and cohorts, where roughly three quarters of people report improvement. Systematic reviews call it effective and safe while stressing that the evidence is still thin and larger trials are needed.

Will ivabradine lower my blood pressure?

Not meaningfully, no, and that’s rather the point. Ivabradine acts only on the sinoatrial node and doesn’t relax blood vessels, so it lowers heart rate without dropping blood pressure the way a beta blocker can. If anything, the recent trial data suggests a small upward nudge in systolic pressure, which is helpful in POTS rather than a problem. That makes it appealing for people whose blood pressure is already on the low side.

Can I get ivabradine for POTS on the NHS?

Possibly, but it is used off label. Ivabradine is licensed in the UK for angina and heart failure, not for POTS, so it is often initiated by a cardiologist or autonomic specialist rather than a GP, and funding can vary. That doesn’t rule it out, it just means it may take a specialist referral and a clear rationale rather than a quick prescription.

If your heart rate is the thing keeping you from moving at all, that’s worth a proper conversation with your doctor, and it’s also exactly the problem our live workshop is built to help you work around, whatever your resting numbers are doing. Whatever you decide about medication, the foundations are what move the needle, and they’re learnable. Our full guide to POTS and dysautonomia walks through the lot, and the same principles carry over to the chronic pain that so often rides along with it. You’re not stuck with this as it is now.

– Adam –

References

[1] Taub PR, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. Journal of the American College of Cardiology 2021;77(7):861-871. doi: 10.1016/j.jacc.2020.12.029
[2] Uppal J, Deol P, Giri P, et al. Ivabradine, Propranolol, and Placebo for Postural Orthostatic Tachycardia Syndrome (POTS): A Randomized Crossover Trial. Journal of the American College of Cardiology 2026. doi: 10.1016/j.jacc.2026.03.167
[3] Ruzieh M, Sirianni N, Ammari Z, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing and Clinical Electrophysiology 2017;40(11):1242-1245. doi: 10.1111/pace.13182
[4] McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace 2011;13(3):427-430. doi: 10.1093/europace/euq390
[5] Barzilai M, Jacob G. The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients. Rambam Maimonides Medical Journal 2015;6(3):e0028. doi: 10.5041/rmmj.10213
[6] Tahir F, Bin Arif T, Majid Z, et al. Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature. Cureus 2020;12(4):e7868. doi: 10.7759/cureus.7868
[7] Melo APG, Moretti MA, Chagas ACP. Use of Ivabradine in the Treatment of Patients with Postural Orthostatic Tachycardia Syndrome (POTS): A Systematic Review. Arquivos Brasileiros de Cardiologia 2025;122(11):e20250347. doi: 10.36660/abc.20250347
[8] Pierson BC, Apilado K, Franzos MA, et al. Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic. Frontiers in Neurology 2025;15:1515486. doi: 10.3389/fneur.2024.1515486
[9] Schiweck N, Langer K, Maier A, et al. Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS). Clinical Autonomic Research 2026;36(1):3-16. doi: 10.1007/s10286-025-01172-2
[10] Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm 2015;12(6):e41-e63. doi: 10.1016/j.hrthm.2015.03.029
[11] Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting – Part 1. Autonomic Neuroscience 2021;235:102828. doi: 10.1016/j.autneu.2021.102828
[12] Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Canadian Journal of Cardiology 2020;36(3):357-372. doi: 10.1016/j.cjca.2019.12.024
[13] Fu Q, VanGundy TB, Shibata S, et al. Exercise Training Versus Propranolol in the Treatment of the Postural Orthostatic Tachycardia Syndrome. Hypertension 2011;58(2):167-175. doi: 10.1161/hypertensionaha.111.172262
[14] Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Autonomic Neuroscience 2018;215:20-27. doi: 10.1016/j.autneu.2018.07.001
[15] Raj SR, Black BK, Biaggioni I, et al. Propranolol Decreases Tachycardia and Improves Symptoms in the Postural Tachycardia Syndrome. Circulation 2009;120(9):725-734. doi: 10.1161/circulationaha.108.846501
[16] Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome – Diagnosis, physiology, and prognosis. Autonomic Neuroscience 2018;215:3-11. doi: 10.1016/j.autneu.2018.02.005